lomustine / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 96 Diseases   29 Trials   29 Trials   1185 News 


«12345678910111213...1516»
  • ||||||||||  Matulane (procarbazine hydrochloride) / Leadiant Biosci
    Journal:  Treating oligodendroglioma - An analysis of a homogeneous 1p/19q-codeleted and isocitrate dehydrogenase-mutant patient cohort. (Pubmed Central) -  May 22, 2023   
    Whereas previous studies often comprise tumors with IDH wild type status and without 1p/19q-codeletion, this homogeneous ODG cohort, as defined by the current WHO classification, demonstrated PFS benefits for various therapies, especially concerning RCT. While this is generally in accordance with comparable studies, more prospective work on homogeneous patient cohorts is required to refine treatment guidelines and to determine the role of TMZ in ODG.
  • ||||||||||  lomustine / Generic mfg., temozolomide / Generic mfg.
    Preclinical, Journal:  Temozolomide and Lomustine Induce Tissue Factor Expression and Procoagulant Activity in Glioblastoma Cells In Vitro. (Pubmed Central) -  May 16, 2023   
    Additionally, PS externalization and induction of inflammatory-associated genes were observed. Overall, the chemotherapeutic modalities TMZ and LOM induced procoagulant activity and increased TF gene and protein expression in all GBM cell lines tested, which may contribute to the increased VTE risk observed in GBM patients undergoing chemotherapy.
  • ||||||||||  lomustine / Generic mfg., temozolomide / Generic mfg.
    Journal:  MRI-Based Deep Learning Tools for MGMT Promoter Methylation Detection: A Thorough Evaluation. (Pubmed Central) -  May 16, 2023   
    Upon relapse, one option for treatment is another chemotherapy, lomustine...Therefore, in this work, beyond the classical performance figures usually displayed, we seek to compute confidence scores to see if a clinical application of such methods can be seriously considered. The systematic approach carried out, using different input configurations and algorithms as well as the exact methylation percentage, led to the following current deep learning methods are unable to determine MGMT promoter methylation from MRI data.
  • ||||||||||  Avastin (bevacizumab) / Roche
    Enrollment change, Trial withdrawal:  Golden Halo, Static Magnetic and Electric Field Device, in Recurrent Glioblastoma (clinicaltrials.gov) -  Apr 21, 2023   
    P=N/A,  N=0, Withdrawn, 
    Findings of this study support the promising effects of everolimus in patients with relapsing or primary refractory Hodgkin lymphoma after autologous HSCT. N=30 --> 0 | Not yet recruiting --> Withdrawn
  • ||||||||||  Cotellic (cobimetinib) / Exelixis, Roche
    Pharmacological characterization of pediatric brain tumor PDX models in a single mouse trial format (Section 1; Poster Board #4) -  Mar 14, 2023 - Abstract #AACR2023AACR_6642;    
    However, several of the targeted agents showed a distinct efficacy profile: Cobimetinib was efficacious in 50% of the HGG (47d vs 28d in the sensitive subset) and Idanasutlin in 80% of the EP models (79d in the sensitive subset vs 52d)...This preclinical validation set gains even more importance using the accompanying molecular profiling data that are available not only for the PDX but also for the donor patient. Together with the breadth and depth of the still growing PDX collection, a unique preclinical platform for the development of drugs as well as companion diagnostics specifically for pediatric brain cancers is now available to the scientific community.
  • ||||||||||  dianhydrogalactitol (VAL-083) / Kintara Therap
    VAL-083 in patients with recurrent glioblastoma treated under expanded access program (Section 34; Poster Board #10) -  Mar 14, 2023 - Abstract #AACR2023AACR_4426;    
    P=N/A
    Current standard-of-care for glioblastoma (GBM) includes surgery followed by concurrent therapy with radiation and temozolomide (TMZ) and adjuvant TMZ...Seven patients received bevacizumab concurrently with VAL-083...Five patients with thrombocytopenia had prior lomustine...Additional safety and efficacy measures will be presented at the meeting.Clincialtrials.gov Identifier: NCT03138629. All EA treatment requests and plans were approved by MD Anderson Cancer Center IRB.
  • ||||||||||  lomustine / Generic mfg.
    Imipramine enhances the efficacy of lomustine by regulating WNT-?-catenin signaling in glioblastoma (Section 18; Poster Board #22) -  Mar 14, 2023 - Abstract #AACR2023AACR_3908;    
    Collectively, the results from our study suggest that Imipramine alone and in combination with Lomustine can be used for treating recurrent GBM. Based on these results, a clinical trial is currently ongoing, where we are testing the efficacy of Imipramine for treating patients with recurrent GBM.
  • ||||||||||  Tabrecta (capmatinib) / Incyte, Novartis
    A Case of Capmatinib used in MET Amplification Glioblastoma (Both in-person and online) -  Mar 12, 2023 - Abstract #AAN2023AAN_3304;    
    He was subsequently treated with Lomustine, however, imaging showed progression of disease...Temozolomide and Bevacizumab are approved chemotherapy regimens for glioblastoma...This shows the importance of gene sequencing tumor cells to help guide treatment plans. Capmatinib likely contributed to the positive response in this patient diagnosed with glioblastoma, the most aggressive primary brain tumor.
  • ||||||||||  Matulane (procarbazine hydrochloride) / Leadiant Biosci
    MRI negative Varicella zoster virus (VZV) plexopathy in a young man with history of malignancy (Both in-person and online) -  Mar 12, 2023 - Abstract #AAN2023AAN_1375;    
    He was diagnosed with shingles and treated with steroids and acyclovir with minimal improvement...Patient was diagnosed with VZV-associated plexopathy, improved with pregabalin and physical therapy...MRI usually shows T2 hyperintensities and thickening of the nerve roots in patients with VZV-associated plexopathy. However, the presentation, onset of symptoms, characteristics of the rash and clinical course was diagnostic of HZ, and the weakness pattern, supported by the EMG findings were diagnostic for VZV-associated plexopathy.
  • ||||||||||  Review, Journal:  Glioblastoma and Other Primary Brain Malignancies in Adults: A Review. (Pubmed Central) -  Feb 27, 2023   
    Treatment of primary CNS lymphoma includes high-dose methotrexate-containing regimens, followed by consolidation therapy with myeloablative chemotherapy and autologous stem cell rescue, nonmyeloablative chemotherapy regimens, or whole brain radiation...Most patients die from progressive disease. First-line therapy for glioblastoma is surgery followed by radiation and the alkylating chemotherapeutic agent temozolomide.
  • ||||||||||  Avastin (bevacizumab) / Roche, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Enrollment closed, Trial completion date, Trial primary completion date:  A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer (clinicaltrials.gov) -  Feb 21, 2023   
    P1,  N=90, Active, not recruiting, 
    First-line therapy for glioblastoma is surgery followed by radiation and the alkylating chemotherapeutic agent temozolomide. Recruiting --> Active, not recruiting | Trial completion date: Mar 2023 --> Mar 2024 | Trial primary completion date: Mar 2023 --> Sep 2022
  • ||||||||||  lomustine / Generic mfg., cyclophosphamide / Generic mfg., etoposide IV / Generic mfg.
    LOMUSTINE, ETOPOSIDE AND CYCLOPHOSPHAMIDE IN CONDITIONING REGIMEN FOR LYMPHOMAS: THE EXPERIENCE OF A BRAZILIAN INSTITUTION (ePoster Area) -  Feb 11, 2023 - Abstract #EBMT2023EBMT_1609;    
    Although longer follow-up time is required, LEC proved to be a secure protocol, with higher overall survival rates than protocols used previously in our environment. The LEC protocol proves to be an option to traditional conditioning regimens and may be an alternative to cytarabine protocols or in situations where frequently used medications are lacking.
  • ||||||||||  Fyarro (nanoparticle albumin-bound rapamycin) / Aadi Biosci
    Trial completion, Trial completion date, Trial primary completion date:  Nab-sirolimus in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma (clinicaltrials.gov) -  Feb 8, 2023   
    P2,  N=62, Completed, 
    Reduced appetite, taste changes, diarrhoea, nausea, vomiting and mucositis are common and impact oral intake.European and American guidelines recommend enteral nutrition (e.g. naso-gastric tube) if a patient is likely to have less than 50% of their nutritional requirements for more than seven days. Active, not recruiting --> Completed | Trial completion date: Dec 2022 --> Aug 2022 | Trial primary completion date: Dec 2022 --> Aug 2022
  • ||||||||||  panobinostat (MTX110) / Biodexa Pharma
    Trial completion date, Trial primary completion date, Combination therapy, Monotherapy:  MAGIC-G1: A Study of Intra-tumoral Administered MTX110 in Patients With Recurrent Glioblastoma (clinicaltrials.gov) -  Jan 30, 2023   
    P1,  N=36, Recruiting, 
    Active, not recruiting --> Completed | Trial completion date: Dec 2022 --> Aug 2022 | Trial primary completion date: Dec 2022 --> Aug 2022 Trial completion date: Sep 2024 --> Aug 2028 | Trial primary completion date: Sep 2024 --> Aug 2028
  • ||||||||||  lomustine / Generic mfg.
    Journal:  Efficacy and tolerability of a 12-week combination chemotherapy followed by lomustine consolidation treatment in canine B- and T-cell lymphoma. (Pubmed Central) -  Dec 13, 2022   
    Although occurrence of HAE was not associated with shorter survival, reliable prediction of patients at risk might be beneficial to allow optimal management of therapy and allocation of supportive measures. Short-term chemotherapy followed by lomustine consolidation leads to compara-ble remission and survival times compared to conventional protocols with cyclophosphamide, doxorubicin, vincristine and prednisolone with acceptable toxicosis in dogs with both B-cell and T-cell lymphoma.
  • ||||||||||  Xpovio (selinexor) / Karyopharm
    Enrollment closed, Combination therapy:  XPORT-GBM-029: A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma (clinicaltrials.gov) -  Dec 12, 2022   
    P1/2,  N=474, Active, not recruiting, 
    Short-term chemotherapy followed by lomustine consolidation leads to compara-ble remission and survival times compared to conventional protocols with cyclophosphamide, doxorubicin, vincristine and prednisolone with acceptable toxicosis in dogs with both B-cell and T-cell lymphoma. Recruiting --> Active, not recruiting
  • ||||||||||  elraglusib (9-ING-41) / Actuate Therap
    Phase classification, Trial completion date, Trial primary completion date, Metastases:  Actuate 1801: 9-ING-41 in Patients with Advanced Cancers (clinicaltrials.gov) -  Dec 7, 2022   
    P2,  N=350, Recruiting, 
    HMOX1, AKT1, and EGFR may represent novel therapeutic targets for lomustine in the clinical treatment of PGBM. Phase classification: P1/2 --> P2 | Trial completion date: Nov 2023 --> Nov 2025 | Trial primary completion date: Nov 2022 --> Nov 2024
  • ||||||||||  methimazole / Generic mfg., lomustine / Generic mfg.
    Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date:  Inducing a Hypothyroxinemic State in Patients With Recurrent Glioblastoma or Gliosarcoma (clinicaltrials.gov) -  Dec 2, 2022   
    P1,  N=0, Withdrawn, 
    Phase classification: P1/2 --> P2 | Trial completion date: Nov 2023 --> Nov 2025 | Trial primary completion date: Nov 2022 --> Nov 2024 N=10 --> 0 | Trial completion date: Feb 2027 --> Oct 2022 | Recruiting --> Withdrawn | Trial primary completion date: Feb 2025 --> Oct 2022
  • ||||||||||  lomustine / Generic mfg., temozolomide / Generic mfg.
    Journal:  Modeling Therapy-Driven Evolution of Glioblastoma with Patient-Derived Xenografts. (Pubmed Central) -  Nov 27, 2022   
    These PDX models mimic changes observed in recurrent GBM in patients, including critical features of therapy-driven tumor evolution. These models can therefore serve as valuable tools for improving our understanding and treatment of recurrent glioma.
  • ||||||||||  Rydapt (midostaurin) / Novartis
    Dexaml-02 : A Phase II Study of Dexamethasone Added to Induction and Postremission Therapy in Older Patients with Newly Diagnosed AML. a French Innovative Leukemia Organization (FILO) Study (ENMCC - Hall D) -  Nov 4, 2022 - Abstract #ASH2022ASH_4168;    
    P2
    Induction chemotherapy regimen consisted in one cycle of idarubicin 8 mg/m²/day, D1 to D5, cytarabine 100 mg/m²/d, CIV D1 to D7, lomustine 200 mg/m²/d, orally at D1 and dexamethasone 10 mg/12h, IV, D1 to D3...The addition of midostaurin in patients with FLT3-ITD or FLT3-TKD mutations was allowed during induction, consolidation and maintenance...Conclusion In older AML patients who are eligible for intensive treatment, adding dexamethasone to induction and consolidation chemotherapy is feasible and associated with a high response rate after a single induction cycle and encouraging overall survival. A historical comparison with the patient population of the LAM-SA 2007 trial (Pigneux A, JCO 2018) will be presented during the meeting to highlight a potential signal of activity.
  • ||||||||||  Avastin (bevacizumab) / Roche
    Journal:  Current therapeutic options for glioblastoma and future perspectives. (Pubmed Central) -  Oct 28, 2022   
    Available standard therapies for recurrent glioblastoma include nitrosureas, bevacizumab and temozolomide rechallenge, as well as TTF devices. Agents that are currently being evaluated in clinical trials include novel targeted therapies, novel chemotherapies, and immunotherapies.
  • ||||||||||  galunisertib (LY2157299) / Eli Lilly
    Trial completion date, Monotherapy:  A Study in Recurrent Glioblastoma (GB) (clinicaltrials.gov) -  Oct 24, 2022   
    P2,  N=180, Active, not recruiting, 
    Not yet recruiting --> Recruiting Trial completion date: Dec 2022 --> Dec 2023